[ad_1]
The EU Medicines Agency wants to advise faster than previously estimated whether it will approve the vaccine from the American manufacturer Moderna. Instead of January 12, the evaluation should take place on January 6.
The European Medicines Agency EMA wants to decide on the approval of another crown vaccine on January 6. It is about the preparation of the American manufacturer Moderna, said the authority in Amsterdam. That’s six days earlier than originally planned.
The EMA had previously stated that it would decide on the Moderna vaccine on January 12. However, the pharmaceutical company had already transmitted the latest data packet today and therefore earlier than expected. “This contains information specific to production for the EU market,” the authority said. In the scientific evaluation of all the data and studies, however, no compromises are made in terms of safety and efficacy.
Vaccination starts inconsistently in the EU
The Moderna vaccine could therefore be the second most likely to hit the EU market. The EMA wants to decide on the approval of the vaccine by the manufacturers Pfizer and Biontech as of next Monday. As soon as the EU Commission gives the green light two days later, vaccinations could be carried out in the EU from December. The approval of the Commission is a matter of form.
In Germany and the other EU countries, vaccinations should start on December 27. In some countries, at the beginning of December 28 or 29, the head of the EU Commission, Ursula von der Leyen, wrote on Twitter. “This is the time for Europe.”
It later became clear, however, that the beginning will probably not be completely smooth after all. The Netherlands, for example, does not want to start vaccinating until January 8, as announced by the Ministry of Health. Commission spokesman Eric Mamer said Wednesday that it was not crucial that everyone started on the same day, but that it was a coordinated start.
Conversations about the Novavax vaccine
The EU Commission announced in the evening that it had also concluded exploratory talks with the pharmaceutical manufacturer Novavax on the delivery of up to 200 million doses of its vaccine. This could further expand the EU vaccine portfolio. The Novavax vaccine is in testing phase three.
The Commission has already contractually secured six vaccines for EU countries. In addition to the vaccine from Biontech / Pfizer and Moderna, agents are from Astrazeneca, Sanofi-GSK, Janssen Pharmaceutica and Curevac.
